Cardiff Oncology (NASDAQ:CRDF) Upgraded to “Hold” by Zacks Investment Research

Cardiff Oncology (NASDAQ:CRDF – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research report issued on Tuesday, Zacks.com reports.

According to Zacks, “Cardiff Oncology Inc. is a clinical-stage biotechnology company. It engages in developing treatment for cancer patients. The company’s product pipeline consists of a Phase 1b/2 study of onvansertib in combination with FOLFIRI/Avastin(R) in KRAS-mutated metastatic colorectal cancer; a Phase 2 study of onvansertib in combination with Zytiga(R) in Zytiga-resistant metastatic castration-resistant prostate cancer; and a Phase 2 study of onvansertib in combination with decitabine in relapsed or refractory acute myeloid leukemia. Cardiff Oncology Inc., formerly known as Trovagene Inc., is based in SAN DIEGO. “

Several other analysts have also recently commented on CRDF. Robert W. Baird decreased their target price on Cardiff Oncology from $13.00 to $9.00 in a report on Tuesday, May 10th. HC Wainwright decreased their price target on Cardiff Oncology from $25.00 to $22.00 in a report on Monday, May 9th. Finally, Maxim Group decreased their price target on Cardiff Oncology from $25.00 to $14.00 in a report on Monday, January 24th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, Cardiff Oncology currently has a consensus rating of “Buy” and a consensus target price of $13.00.

Cardiff Oncology stock traded down $0.05 during mid-day trading on Tuesday, hitting $1.19. 568,119 shares of the company were exchanged, compared to its average volume of 778,091. The business has a fifty day moving average of $1.87 and a 200 day moving average of $3.67. Cardiff Oncology has a 1-year low of $1.13 and a 1-year high of $8.58. The company has a market capitalization of $51.53 million, a PE ratio of -1.45 and a beta of 2.04.

Cardiff Oncology (NASDAQ:CRDF – Get Rating) last released its quarterly earnings data on Friday, May 6th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.02). Cardiff Oncology had a negative return on equity of 25.12% and a negative net margin of 9,447.37%. Research analysts anticipate that Cardiff Oncology will post -1.05 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in CRDF. Quantbot Technologies LP acquired a new position in Cardiff Oncology in the first quarter valued at about $28,000. XTX Topco Ltd acquired a new stake in shares of Cardiff Oncology during the first quarter worth about $62,000. Citigroup Inc. raised its position in shares of Cardiff Oncology by 105.1% during the fourth quarter. Citigroup Inc. now owns 10,574 shares of the company’s stock worth $64,000 after purchasing an additional 5,419 shares during the period. Metropolitan Life Insurance Co NY acquired a new stake in shares of Cardiff Oncology during the third quarter worth about $74,000. Finally, Invesco Ltd. acquired a new stake in shares of Cardiff Oncology during the second quarter worth about $87,000. 56.43% of the stock is currently owned by hedge funds and other institutional investors.

Cardiff Oncology Company Profile (Get Rating)

Cardiff Oncology, Inc, a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

Recommended Stories